First Patients With Macular Degeneration and Stargardt’s Disease Receive Stem Cell Treatment

July 21, 2011

Advanced Cell Technology announced the dosing of the first patients in each of its two Phase 1/2 clinical trials for Stargardt’s macular dystrophy and dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were treated Tuesday (July 12) by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA’s Jules Stein Eye Institute.

For the complete story please follow this link.




Jump down to form below to submit your own comments

Comments are closed.